Supplementary Table 1 -A pharmacovigilance study of terbinafine indication and liver enzyme elevation
Published: 7 July 2022| Version 1 | DOI: 10.17632/n8pkb4tzyz.1
Contributor:
Ivan Litvinov
Description
Supplemental Table I. Reporting Numbers according to Age Group and Sex for Both FAERS and CVARO Databases. Details on patient demographics, notably age and sex, of patients reporting LEE events with terbinafine usage.
Files
Institutions
McGill University
Categories
Statistical Table